Diamedica Therapeutics Inc (DMAC) Stock Price, Quote & News

Company Profile

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company develops DM300, which is a recombinant human ulin...

Industry: Biotechnology

Sector: Healthcare

Phone: 763 496 5454

Website: www.diamedica.com

Address:

301 Carlson Parkway, Suite 210, Minneapolis, United States

Stock_picker_trader May. 7 at 9:37 PM

$DMAC now til Q1 2027 is gonna get exciting. This company is starting to pick up steam now. Nice questions from analysts on the call today.

0 · Reply

Pegger May. 7 at 8:23 PM

$DMAC I guess it’s not just me, but it felt like someone was accumulating shares today

0 · Reply

Sukitt May. 7 at 7:20 PM

$DMAC Today should be seen as a gift. 🎁 💎💪🏻

0 · Reply

StocktwitsEarnings May. 7 at 10:00 AM

$DMAC Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.19 down -5.56% YoY • DiaMedica Therapeutics Inc. expects to incur substantial operating losses and negative cash flows, anticipated to moderately increase due to ongoing DM199 clinical development. Current cash resources are sufficient for planned operations for at least the next 12 months.

0 · Reply

Relee187200 May. 6 at 11:49 PM

$DMAC Why no reaction to earnings?

0 · Reply

MedCred Apr. 27 at 12:57 PM

$DMAC stroke trial should be close to 150. Or even 160. I’d think recruitment at least 10-20 per month. 63 sites. Would be nice to hear something about pace of enrollment.

0 · Reply

Stock_picker_trader Apr. 16 at 7:26 PM

$DMAC if after the interim analysis of stroke continues it would take the following quarter for enrollment to be complete

1 · Reply

Relee187200 Apr. 15 at 2:40 AM

$DMAC Big down after hours

0 · Reply

RealAvidTrader Apr. 13 at 7:49 PM

$DMAC Very Small Add - Buy Alert in Our Group $5.78 (Post in Comments Below) - Dipped Off No News, No Real Reason To Be Down. Love It Under $6.00 as Short Term (Temporary Bottom) https://youtu.be/CSd0b1RGuh0

1 · Reply

Relee187200 Apr. 8 at 7:35 PM

$DMAC Why down so much today?

2 · Reply

DiaMedica Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

May 7, 2026, 8:00 AM EDT - 6 days ago

DiaMedica Therapeutics Earnings Call Transcript: Q1 2026

2026-05-07T01:03:34.000Z - 6 days ago

DiaMedica Therapeutics reports Q1 EPS (19c), consensus (19c)

May 6, 2026, 4:30 PM EDT - 6 days ago

DiaMedica Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights

Apr 30, 2026, 8:25 AM EDT - 13 days ago

DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026

Apr 16, 2026, 11:00 AM EDT - 26 days ago

DiaMedica Therapeutics Transcript: Biotech Resurgence: Platforms and Pipelines of Today's Innovators

Mar 31, 2026, 8:00 AM EDT - 6 weeks ago

DiaMedica Therapeutics Earnings Call Transcript: Q4 2025

2026-03-30T20:50:55.000Z - 6 weeks ago

DiaMedica Therapeutics reports FY25 EPS (70c), consensus (68c)

Mar 30, 2026, 4:45 PM EDT - 6 weeks ago

DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights

Mar 23, 2026, 8:25 AM EDT - 7 weeks ago

DiaMedica Therapeutics to Report Fourth Quarter 2025 Financial Results and Provide a Business Update March 31, 2026

2026-03-05T12:59:38.000Z - 2 months ago

DiaMedica Therapeutics receives Health Canada clearance to initiate DM199 study

Mar 5, 2026, 7:35 AM EST - 2 months ago

DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia

Feb 24, 2026, 9:23 AM EST - 2 months ago

DiaMedica Therapeutics to Participate in Upcoming March Investor Conferences

Jan 16, 2026, 5:00 PM EST - 4 months ago

DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-01-05T13:46:27.000Z - 4 months ago

DiaMedica Therapeutics named a Top Idea for 2026 at Lake Street

2025-12-18T14:16:01.000Z - 5 months ago

DiaMedica Therapeutics provides DM199 update following FDA meeting

Dec 18, 2025, 8:45 AM EST - 5 months ago

DiaMedica Therapeutics Provides DM199 Preeclampsia Program Update Following Pre-IND Meeting with FDA

2025-11-14T13:10:30.000Z - 6 months ago

DiaMedica Therapeutics initiated with an Overweight at Cantor Fitzgerald

2025-11-14T11:20:28.000Z - 6 months ago

DiaMedica Therapeutics initiated with an Overweight at Cantor Fitzgerald

Nov 13, 2025, 8:00 AM EST - 6 months ago

DiaMedica Therapeutics Earnings Call Transcript: Q3 2025

2025-11-12T21:35:21.000Z - 6 months ago

DiaMedica Therapeutics reports Q3 EPS (17c), consensus (16c)

Nov 12, 2025, 4:30 PM EST - 6 months ago

DiaMedica Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights

Nov 10, 2025, 8:15 AM EST - 6 months ago

DiaMedica Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

Nov 6, 2025, 4:15 PM EST - 6 months ago

DiaMedica Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update November 13, 2025

2025-10-30T11:07:26.000Z - 6 months ago

DiaMedica Therapeutics initiated with a Buy at TD Cowen

Sep 29, 2025, 4:15 PM EDT - 8 months ago

DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Sep 5, 2025, 8:30 AM EDT - 8 months ago

DiaMedica Therapeutics to Participate in Upcoming Investor Conferences

Sep 4, 2025, 9:10 AM EDT - 8 months ago

DiaMedica Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Sep 2, 2025, 8:23 AM EDT - 9 months ago

DiaMedica Therapeutics to Participate in Cantor Global Healthcare Conference

Aug 13, 2025, 8:00 AM EDT - 9 months ago

DiaMedica Therapeutics Earnings Call Transcript: Q2 2025

2025-08-12T21:15:22.000Z - 9 months ago

DiaMedica Therapeutics files $100M mixed securities shelf

2025-08-12T20:20:17.000Z - 9 months ago

DiaMedica Therapeutics reports Q2 EPS (18c), consensus (19c)

Aug 12, 2025, 4:15 PM EDT - 9 months ago

DiaMedica Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights

2025-08-06T13:35:30.000Z - 9 months ago

DiaMedica Therapeutics CMO Lorianne Masuoka resigns, Julie Krop succeeds

PRTC

Aug 6, 2025, 8:00 AM EDT - 10 months ago

DiaMedica Therapeutics Appoints Julie Krop, MD, as Chief Medical Officer

Aug 5, 2025, 4:15 PM EDT - 10 months ago

DiaMedica Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update August 13, 2025

2025-08-01T12:36:24.000Z - 10 months ago

DiaMedica Therapeutics files to sell 8.61M common shares for holders

Jul 23, 2025, 4:30 PM EDT - 10 months ago

DiaMedica Therapeutics Announces Closing of $30.1 Million Private Placement

2025-07-21T13:20:10.000Z - 10 months ago

DiaMedica Therapeutics to sell 8.606M shares at $3.50 in private placement

Jul 21, 2025, 8:00 AM EDT - 10 months ago

DiaMedica Therapeutics Raises $30 Million in Private Placement to Accelerate Industry Leading Preeclampsia and Fetal Growth Restriction Pipeline

2025-07-18T13:00:18.000Z - 10 months ago

DiaMedica Therapeutics price target raised to $11 from $8 at Craig-Hallum

2025-07-18T12:40:25.000Z - 10 months ago

DiaMedica Therapeutics price target raised to $14 from $11 at Lake Street

2025-07-18T10:27:29.000Z - 10 months ago

DiaMedica Therapeutics price target raised to $12 from $10 at H.C. Wainwright

Jul 17, 2025, 4:30 PM EDT - 10 months ago

DiaMedica Therapeutics Transcript: Study Result

Jul 17, 2025, 8:00 AM EDT - 10 months ago

DiaMedica Therapeutics Reports Positive Interim Phase 2 Preeclampsia Results: Statistically Significant Reductions in Blood Pressure and No Placental Transfer

Jun 24, 2025, 8:30 AM EDT - 11 months ago

DiaMedica Therapeutics Announces Inclusion in the Russell 2000® and Russell 3000® Indexes

May 28, 2025, 8:00 AM EDT - 1 year ago

DiaMedica Therapeutics Transcript: Status Update

May 22, 2025, 8:30 AM EDT - 1 year ago

DiaMedica Therapeutics to Present at Jefferies Global Healthcare Conference 2025

May 20, 2025, 3:30 PM EDT - 1 year ago

DiaMedica Therapeutics Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 19, 2025, 9:00 AM EDT - 1 year ago

DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia

May 14, 2025, 4:30 PM EDT - 1 year ago

DiaMedica Therapeutics Announces Poster Presentation at European Stroke Organisation Conference – ESOC 2025

May 14, 2025, 8:00 AM EDT - 1 year ago

DiaMedica Therapeutics Earnings Call Transcript: Q1 2025

May 13, 2025, 4:30 PM EDT - 1 year ago

DiaMedica Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Highlights

May 8, 2025, 4:00 PM EDT - 1 year ago

DiaMedica Therapeutics to Participate in Upcoming Investor Conferences in May

May 7, 2025, 8:30 AM EDT - 1 year ago

DiaMedica Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update May 14, 2025

Mar 18, 2025, 8:00 AM EDT - 1 year ago

DiaMedica Therapeutics Earnings Call Transcript: Q4 2024

Mar 17, 2025, 4:30 PM EDT - 1 year ago

DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2024 Financial Results

Mar 11, 2025, 8:23 AM EDT - 1 year ago

DiaMedica Therapeutics to Report Fourth Quarter 2024 Financial Results and Provide a Business Update March 18, 2025

Feb 24, 2025, 8:30 AM EST - 1 year ago

DiaMedica Therapeutics Appoints Daniel J. O'Connor to the Board of Directors

Feb 20, 2025, 8:15 AM EST - 1 year ago

DiaMedica Therapeutics Announces Publication of DM199's Mechanism of Action for the Treatment of Acute Ischemic Stroke (AIS) in the Journal Stroke

Feb 10, 2025, 4:15 PM EST - 1 year ago

DiaMedica Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Dec 3, 2024, 8:25 AM EST - 1 year ago

DiaMedica Therapeutics Announces Formation of Scientific Advisor Board to Support the Development of DM199 for the Treatment of Preeclampsia

Nov 14, 2024, 8:00 AM EST - 1 year ago

DiaMedica Therapeutics Earnings Call Transcript: Q3 2024

Nov 13, 2024, 4:20 PM EST - 1 year ago

DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results

Nov 13, 2024, 4:05 PM EST - 1 year ago

DiaMedica Therapeutics Announces Dosing of First Patient in Phase 2 Trial of DM199 in the Treatment of Preeclampsia

Nov 12, 2024, 8:23 AM EST - 1 year ago

DiaMedica Therapeutics to Participate in Upcoming Craig-Hallum 15th Annual Alpha Select Conference

Nov 6, 2024, 8:32 AM EST - 1 year ago

DiaMedica Therapeutics to Provide a Business Update and Report Third Quarter 2024 Financial Results November 14, 2024

Oct 9, 2024, 8:27 AM EDT - 1 year ago

DiaMedica Therapeutics Announces Regulatory Approval to Begin Phase 2 Trial of DM199 in the Treatment of Preeclampsia

Sep 4, 2024, 4:15 PM EDT - 1 year ago

DiaMedica Therapeutics Upcoming Conference Participation

Aug 8, 2024, 8:00 AM EDT - 1 year ago

DiaMedica Therapeutics Earnings Call Transcript: Q2 2024

Aug 7, 2024, 4:15 PM EDT - 1 year ago

DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2024 Financial Results

Aug 1, 2024, 8:20 AM EDT - 1 year ago

DiaMedica Therapeutics to Provide a Business Update and Report Second Quarter 2024 Financial Results August 8, 2024

Jul 11, 2024, 8:00 AM EDT - 1 year ago

DiaMedica Therapeutics Releases Preeclampsia White Paper and Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia

Jul 1, 2024, 8:00 AM EDT - 2 years ago

DiaMedica Therapeutics Announces Closing of $11.8 Million Private Placement

Jun 27, 2024, 8:00 AM EDT - 2 years ago

DiaMedica Therapeutics Transcript: Status Update

Jun 26, 2024, 8:15 AM EDT - 2 years ago

DiaMedica Therapeutics Announces $11.8 Million Private Placement

Jun 26, 2024, 8:00 AM EDT - 2 years ago

DiaMedica Therapeutics Announces Expansion of DM199 (Rinvecalinase Alfa) Program Into Preeclampsia

May 9, 2024, 8:00 AM EDT - 2 years ago

DiaMedica Therapeutics Earnings Call Transcript: Q1 2024

May 8, 2024, 4:30 PM EDT - 2 years ago

DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2024 Financial Results

May 2, 2024, 8:55 AM EDT - 2 years ago

DiaMedica Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update May 9, 2024

Apr 17, 2024, 4:08 PM EDT - 2 years ago

DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke

Mar 20, 2024, 8:00 AM EDT - 2 years ago

DiaMedica Therapeutics Earnings Call Transcript: Q4 2023

Mar 19, 2024, 4:15 PM EDT - 2 years ago

DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results

Stock_picker_trader May. 7 at 9:37 PM

$DMAC now til Q1 2027 is gonna get exciting. This company is starting to pick up steam now. Nice questions from analysts on the call today.

0 · Reply

Pegger May. 7 at 8:23 PM

$DMAC I guess it’s not just me, but it felt like someone was accumulating shares today

0 · Reply

Sukitt May. 7 at 7:20 PM

$DMAC Today should be seen as a gift. 🎁 💎💪🏻

0 · Reply

StocktwitsEarnings May. 7 at 10:00 AM

0 · Reply

Relee187200 May. 6 at 11:49 PM

$DMAC Why no reaction to earnings?

0 · Reply

MedCred Apr. 27 at 12:57 PM

$DMAC stroke trial should be close to 150. Or even 160. I’d think recruitment at least 10-20 per month. 63 sites. Would be nice to hear something about pace of enrollment.

0 · Reply

Stock_picker_trader Apr. 16 at 7:26 PM

$DMAC if after the interim analysis of stroke continues it would take the following quarter for enrollment to be complete

1 · Reply

Relee187200 Apr. 15 at 2:40 AM

$DMAC Big down after hours

0 · Reply

RealAvidTrader Apr. 13 at 7:49 PM

1 · Reply

Relee187200 Apr. 8 at 7:35 PM

$DMAC Why down so much today?

2 · Reply

garrstev88 Apr. 8 at 8:24 AM

$DMAC calm post-market with balanced liquidity If bids fail to hold, price may stall and enter sideways chop

0 · Reply

RealAvidTrader Apr. 7 at 12:54 PM

$DMAC The Best $6 Stock Setup? (Deep Dive Analysis) https://youtu.be/CSd0b1RGuh0

0 · Reply

OfficialStocktwitsUser Apr. 1 at 11:19 PM

$DMAC RSI: 31.53, MACD: -0.3596 Vol: 0.42, MA20: 7.15, MA50: 7.82 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

TalkMarkets Apr. 1 at 1:21 AM

DiaMedica Therapeutics Closes 2025 With Strengthened Cash Position And Pipeline Momentum $DMAC https://talkmarkets.com/article/diamedica-therapeutics-closes-2025-with-strengthened-cash-position-and-pipeline-momentum-1775006375

1 · Reply

Stock_picker_trader Apr. 1 at 12:41 AM

$DMAC Dm199 KOL manuscript https://d1io3yog0oux5.cloudfront.net/_2a43f49bcff7dd6b6016aa912d2127c0/diamedica/db/197/3305/presentation/%5BCall+Transcript%5D+KOL+Webinar+Highlights+DM-199+For+Pre-Eclampsia+Looks+Like+a+Real+Drug.pdf

0 · Reply

MedCred Mar. 31 at 7:58 PM

$DMAC Good strategy and new avenue ! resistant hypertension in CKD. Huuuge market !! Dm199 definitely lowers blood pressure.

0 · Reply

Stock_picker_trader Mar. 31 at 4:07 PM

$DMAC CKD trial coming along with preeclampsia and stroke https://pubmed.ncbi.nlm.nih.gov/41860188/

0 · Reply

WallStreetBuyDip Mar. 31 at 12:52 AM

many rushing $DMAC while I wait for H% to be very low. this is what I mean.

0 · Reply

Junior31 Mar. 30 at 10:25 PM

$DMAC The below captures well the reality of the situation...

0 · Reply

Junior31 Mar. 30 at 10:25 PM

$DMAC Official STOCKTWITS Representative BEARISH DiaMedica has experienced and continues to experience slower than expected site activations and enrollment in its ReMEDy2 trial, potentially due to hospital staffing shortages and competition for trial subjects. DiaMedica has incurred significant operating losses in every reporting period since its inception, with a net loss of $32.8M for the year ended December 31, 2025, and may never achieve or sustain profitability.

0 · Reply

StocktwitsEarnings Mar. 30 at 10:20 PM

$DMAC Q4 '25 Earnings Results & Recap Reported GAAP EPS of -$0.16 up 11.11% YoY

0 · Reply

Junior31 Mar. 30 at 9:49 PM

$DMAC This company has LONG and VERY uncertain road in front of them and they are gonna burn through their remaining cash very quickly. Sand through the hourglass situation. Offering needed sooner than later. Not a surprise at all.

0 · Reply

Market Cap	347.55M
Revenue (ttm)	0.00
Net Income (ttm)	-32.77M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	185,400
Avg Vol	201,348
Day's Range	N/A - N/A
Shares Out	53.88M
Stochastic %K	62%
Beta	0.99
Analysts	Strong Sell
Price Target	$15.50